BRAF inhibitor-resistant and BRAF inhibitor-sensitive melanomas display distinct transcriptional profiles: in fact, drug-sensitive cells display high MITF expression, associated with low NF-kB signaling and low receptor tyrosine kinase AXL, while drug-sensitive cells display the opposite phenotype, with low MITF expression, associated with high NF-κβ and AXL activity [182,183]. The gene discussed is AXL; the disease is melanoma.